Alex Herrera, MD

Articles

Dr Herrera on Nivolumab vs Brentuximab Vedotin Plus AVD in Hodgkin Lymphoma

October 28th 2024

Alex Herrera, MD, discusses safety and efficacy outcomes with nivolumab plus AVD vs brentuximab vedotin plus AVD in advanced classic Hodgkin lymphoma.

Lunning and Herrera Highlight Frontline Hodgkin Lymphoma Management Strategies

March 18th 2024

Dr Lunning sits down with Alex Herrera, MD, to discuss the frontline management of Hodgkin lymphoma, including the SWOG 1826 trial.

Gaining Ground in Gynecologic and Hematologic Cancers at ASCO 2023: Drs Herrera, Westin, and Jabbour

June 5th 2023

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic oncology during the conference.

Dr. Herrera on the Potential for Frontline CAR T-Cell Therapy in DLBCL

September 20th 2021

Alex Herrera, MD, discusses the potential for CAR T-cell therapy in earlier lines of treatment for patients with diffuse large B-cell lymphoma.

Dr. Herrera on the Utility of CAR T-Cell Therapy in Hematologic Cancers

September 3rd 2021

Alex Herrera, MD, discusses the utility of CAR T cells in patients with hematologic cancers.

Dr. Herrera on Camidanlumab Tesirine in Relapsed/Refractory Hodgkin Lymphoma

March 19th 2021

Alex Herrera, MD, discusses the potential role of camidanlumab tesirine in patients with relapsed/refractory Hodgkin Lymphoma, which is currently being examined in a phase 2 clinical trial.

Dr. Herrera Discusses Polatuzumab Vedotin in DLBCL

December 14th 2017

Alex Herrera, MD, assistant professor, Department of Hematology and Hematologic Cell Transplantation, City of Hope, discusses polatuzumab vedotin in diffuse large B-cell lymphoma.

Dr. Herrera on Next Steps of Drug Combinations for Hodgkin Lymphoma

February 17th 2017

Alex Herrera, MD, assistant professor, Department of Hematology and Hematologic Cell Transplantation, City of Hope, discusses next steps for a phase I/II study of brentuximab vedotin (Adcetris) in combination with nivolumab (Opdivo) in patients with relapsed or refractory Hodgkin lymphoma.